natgillin/translations-raw huggingface dataset:
Attach the needle for reconstitution (the bigger needle) to the syringe and draw up some air into the syringe by pulling the plunger to approximately the 1 ml mark.
Pritrdite iglo za pripravo (večjo iglo) na brizgo in v brizgo potegnite nekaj zraka tako, da bat potegnete približno do oznake 1 ml.
Then, insert the needle into the vial, push the plunger to expel the air, turn the vial upside down and gently draw up all the solvent.
Nato iglo zabodite v vialo, potisnite bat, da iztisnete zrak, obrnite vialo na glavo in previdno izvlecite ves vehikel.
Set the syringe down carefully on the work-surface taking care not to touch the needle.
Pazljivo odložite brizgo na delovno površino in pri tem pazite, da se ne dotaknete igle.
Preparing the injection solution:
Priprava raztopine za injiciranje:
Immediately inject the solution:
Raztopino takoj injicirajte.
Firmly pinch the skin together and insert the needle at a 45° to 90° angle using a dart-like motion.
Kožo trdno stisnite skupaj in iglo zabodite pod kotom 45 ° do 90 ° z gibom, podobnim metu sulice.
37 If you take more Ovitrelle than you should:
37 Če ste uporabili večji odmerek zdravila Ovitrelle, kot bi smeli
Like all medicines, Ovitrelle can cause side effects, although not everybody gets them.
Kot vsa zdravila, ima lahko tudi zdravilo Ovitrelle neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Diarrhoea, depression, irritability, restlessness and breast pain have also been reported in some cases and are considered uncommon.
O driski, depresiji, razdražljivosti, nemiru in bolečih dojkah so prav tako poročali v nekaterih primerih in štejejo za občasne neželene učinke.
Do not use after the expiry date which is stated on the label after EXP.
Zdravila Ovitrelle ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki viale poleg oznake EXP.
Merck Serono S. p. A., Via delle Magnolie 15, I-70026 Modugno (Bari), Italy
Merck Serono S. p. A., Via delle Magnolie 15, I- 70026 Modugno (Bari), Italija
Choriogonadotropin alfa
Ovitrelle 250 mikrogramov/ 0, 5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Horiogonadotropin alfa
Before you use Ovitrelle 3.
Kaj morate vedeti preden boste uporabili zdravilo Ovitrelle 3.
How to use Ovitrelle 4.
Kako uporabljati zdravilo 4.
Ovitrelle is also used in women who do not produce eggs (a condition called anovulation), or who produce too few eggs (oligo-ovulation).
Ovitrelle uporabljamo tudi pri ženskah, pri katerih jajčeca ne nastajajo (to stanje imenujemo anovulacija) ali jih nastaja premalo (oligoovulacija).
BEFORE YOU USE OVITRELLE
KAJ MORATE VEDETI PREDEN BOSTE UPORABILI ZDRAVILO OVITRELLE
Do not take Ovitrelle:
Ne uporabljajte zdravila Ovitrelle:
- If you have unexplained vaginal bleeding
- če imate nepojasnjeno krvavitev iz nožnice
- If you have been diagnosed as having ovarian, uterine or breast cancer
- če so vam odkrili raka na jajčniku, maternici ali dojki
- If you have had a tumour of the hypothalamus or pituitary gland
- če ste imeli tumor hipotalamusa ali žleze hipofize
- If you are allergic (hypersensitive) to choriogonadotropin or any of the ingredients of Ovitrelle
Ovitrelle,
- If you have any condition which would make a normal pregnancy impossible (e. g. absent
- če imate katerokoli stanje, ki onemogoča normalno nosečnost (npr. nimate maternice, imate
uterus, ovaries which have not developed properly, fibroids) or have you been through the menopause
nepravilno razvita jajčnika, miome), ali ste že po menopavzi
- If you have had an extrauterine pregnancy within the last 3 months
- če ste imeli v zadnjih 3 mesecih zunajmaternično nosečnost.
42 Take special care with Ovitrelle:
42 Bodite posebno pozorni pri uporabi zdravila Ovitrelle
If you have significant abdominal pain or discomfort, do not give yourself the injection, and speak to your doctor or nurse as soon as possible.
Če imate v trebuhu močne bolečine ali nelagodje, ne uporabite injekcije in se čim prej pogovorite s svojim zdravnikom ali medicinsko sestro.
Compared with natural conception, the frequency of multiple pregnancies and births is increased in patients receiving this treatment.
Večplodne nosečnosti in rostva so pri bolnicah, ki prejemajo to zdravljenje, pogostejši kot pri ženskah, ki naravno zanosijo.
Always take Ovitrelle exactly as your doctor has told you.
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom.
Your doctor will have explained exactly when to give the injection.
Običajen odmerek zdravila Ovitrelle je 1 napolnjena injekcijska brizga (250 mikrogramov/ 0, 5 ml), ki se daje kot enkratna injekcija. Vaš zdravnik vam je natančno pojasnil, kdaj dati injekcijo.
Each pre- filled syringe is for single use only, only clear solution without particles should be used.
Uporabiti se sme samo bistro raztopino brez delcev.
Sometimes the injection will be given to you by a doctor or nurse, or you or your partner may be trained to give the injection at home.
V nekaterih primerih daje injekcijo vaš zdravnik ali medicinska sestra, ali pa lahko naučijo vas ali vašega partnerja, kako dajati injekcijo doma.
Please note that alcohol swabs are not contained in the package.
Prosimo upoštevajte, da alkoholna tampona nista priložena v pakiranju.
two alcohol swabs, one pre-filled syringe containing the medicinal product
dva alkoholna tampona napolnjeno injekcijsko brizgo z zdravilom.
If you forget to take Ovitrelle
Če ste pozabili uporabiti zdravilo Ovitrelle
The majority of side effects seen to date have been mild or moderate.
Večina doslej opaženih je bila blagih ali zmernih.
Ovarian hyperstimulation syndrome has been observed in approximately 4% of the patients in clinical trials; most of these cases were mild or moderate in nature.
V kliničnih raziskavah so sindrom hiperstimulacije jajčnikov opazili pri približno 4% bolnic; večinoma je bil blage ali zmerne narave.
Blood in the peritoneal cavity, respiratory difficulties are possible complications of ovarian hyperstimulation syndrome.
Možna zapleta sindroma hiperstimulacije jajčnikov sta kri v peritonealni votlini in težave z dihanjem. Za ta sindrom so značilne velike ciste na jajčnikih.
First symptoms of ovarian hyperstimulation are pain in the lower abdominal region, possibly in combination with nausea, vomiting and weight gain.
Prvi znaki hiperstimulacije jajčnikov so bolečina v spodnjem predelu trebuha, ki jo lahko spremljajo slabost, bruhanje in povečevanje telesne mase.
Should the above mentioned symptoms occur, a careful medical examination is indicated as soon as possible.
Če opazite zgoraj opisane znake, morate čimprej na natančen zdravniški pregled.
Common side effects reported include abdominal pain, nausea and vomiting, headache, injection site inflammation and reaction, dizziness.
Običajni neželeni učinki o katerih so poročali vključujejo bolečino v trebuhu, slabost in bruhanje, glavobol, vnetje in reakcije na mestu injiciranja, omotico.
Extrauterine pregnancy, ovarian torsion (a condition affecting the ovaries) and other complications may arise from the assisted conception techniques your doctor may use.
Pri postopkih asistirane oploditve, ki jih lahko uporabi vaš zdravnik, se lahko pojavijo zunajmaternična nosečnost, torzija jajčnika (stanje, ki prizadene jajčnika) in drugi zapleti.
44 Do not use after the expiry date which is stated on the label after EXP.
44 Zdravila Ovitrelle ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki napolnjene injekcijske brizge poleg oznake EXP.
Store in a refrigerator (2°C-8°C).
Shranjujte pri temperaturi med 2°C in 8°C (v hladilniku).
Ovitrelle 250 micrograms solution for injection may be stored at room temperature (at or below +25° C) for up to 30 days without being refrigerated again during this period, and must be discarded if not used during these 30 days.
Ovitrelle 250 mikrogramov raztopino za injiciranje lahko shranjujete pri sobni temperaturi (pri ali pod +25 °C) do 30 dni, brez ponovnega shranjevanja v hladilniku v tem času in jo morate zavreči, če je ne uporabite v teh 30 dneh.
Ovitrelle is for single use only.
Ovitrelle je samo za enkratno uporabo.
The active substance is choriogonadotropin alfa.
Zdravilna učinkovina je horiogonadotropin alfa.
Each pre-filled syringe contains 250 micrograms / 0.5 ml (equivalent to 6500 IU).
Vsaka napolnjena injekcijska brizga vsebuje 250 mikrogramov / 0, 5 ml (kar ustreza 6500 i. e.).
The other ingredients are mannitol, methionine, poloxamer 188, diluted phosphoric acid, sodium hydroxide, water for injections.
Pomožne snovi so manitol, metionin, poloksamer 188, razredčena fosforjeva kislina, natrijev hidroksid, voda za injekcije.
Ovitrelle is provided as solution for injection.
Ovitrelle je v obliki raztopine za injiciranje.
Pandemrix is a vaccine that is given by injection.
Zdravilo Pandemrix je cepivo, ki se daje z injiciranjem.
It contains parts of influenza (flu) viruses that have been inactivated (killed).
Vsebuje dele virusov gripe, ki so bili inaktivirani (ubiti).
Pandemrix contains a flu strain called ‘ A/ VietNam/ 1194/ 2005 NIBRG-14’ (H5N1).
Zdravilo Pandemrix vsebuje sev gripe, imenovan » A/ VietNam/ 1194/ 2005 NIBRG- 14 « (H5N1).
Pandemrix is a vaccine for use in adults aged between 18 and 60 years to prevent ‘ pandemic’ flu.
Zdravilo Pandemrix je cepivo, namenjeno za uporabo pri odraslih v starosti od 18 do 60 let za preprečevanje „ pandemične “ gripe.
It should only be used once a flu pandemic has been officially declared by the World Health Organization (WHO) or European Union (EU).
Uporabi se lahko šele potem, ko Svetovna zdravstvena organizacija (WHO) ali Evropska unija (EU) uradno razglasi pandemijo gripe.
A flu pandemic happens when a new type (strain) of flu virus appears that can spread easily from person to person because people have no immunity (protection) against it.
Pandemija gripe nastopi, ko se pojavi nova vrsta (sev) virusa gripe, ki se lahko brez težav širi s človeka na človeka, ker ljudje nanj niso imuni (zaščiteni proti njemu).
Pandemrix would be given according to official recommendations.
Zdravilo Pandemrix se daje v skladu z uradnimi priporočili.
Pandemrix is given by injection into the upper arm muscle in two doses, at least three weeks apart.
Zdravilo Pandemrix se daje z injiciranjem v mišico nadlakti v dveh odmerkih v razmaku najmanj treh tednov.
Pandemrix is a ‘ mock-up’ vaccine.
Zdravilo Pandemrix je „ modelno “ cepivo.
This is a special type of vaccine that is designed to help with the management of a pandemic.
To je posebna vrsta cepiva, razvita v pomoč pri obvladovanju pandemije.
They can then test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing the pandemic is included.
To cepivo lahko nato preizkusijo, da bi preverili, kako se ljudje nanj odzivajo, na podlagi česar lahko predvidevajo, kako se bodo ljudje odzivali, ko se bo pojavil sev gripe, ki povzroča pandemijo.
Vaccines work by ‘ teaching’ the immune system (the body’ s natural defences) how to defend itself against a disease.
Cepiva delujejo tako, da imunski sistem (naravne obrambne mehanizme telesa) „ učijo “, kako naj se brani pred boleznijo.
Pandemrix contains small amounts of haemagglutinins (proteins from the surface) of a virus called H5N1.
Zdravilo Pandemrix vsebuje majhno količino hemaglutininov (beljakovin s površine) virusa, imenovanega H5N1.
The virus has first been inactivated (killed) so that it does not cause any disease.
Virus je bil najprej inaktiviran (ubit), tako da ne povzroča bolezni.
If a pandemic starts, the virus strain in Pandemrix will be replaced by the strain causing the pandemic before the vaccine can be used.
V primeru izbruha pandemije bo sev virusa v zdravilu Pandemrix nadomeščen s sevom, ki povzroča pandemijo, preden bo cepivo mogoče uporabljati.
This will help to protect against the disease caused by the virus.
To prispeva k obrambi pred boleznimi, ki jih ta virus povzroča.
Before use, the vaccine will be made up by mixing together a suspension that contains the virus particles with an emulsion.
Pred uporabo je treba cepivo pripraviti z mešanjem suspenzije, ki vsebuje delce virusa, in emulzije.
The resulting ‘ emulsion’ will then be injected.
Tako dobljeno „ emulzijo “ nato injiciramo.
The effects of Pandemrix were first tested in experimental models before being studied in humans.
Učinki zdravila Pandemrix so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The main study of Pandemrix included 400 healthy adults and compared the ability of different doses of Pandemrix, with or without the adjuvant, to trigger the production of antibodies (‘ immunogenicity’).
V glavno študijo zdravila Pandemrix je bilo vključenih 400 zdravih odraslih.
The participants received two injections of Pandemrix containing one of four different doses of haemagglutinin.
V njej so primerjali učinkovitost različnih odmerkov zdravila Pandemrix, z adjuvansom ali brez njega, pri sprožanju tvorbe protiteles (imunogenosti).
The main measures of effectiveness were the levels of antibodies against the flu virus in the blood at three different times: before vaccination, on the day of the second injection (day 21) and 21 days later (day 42).
Glavno merilo učinkovitosti je bila koncentracije protiteles proti virusu gripe v krvi ob treh različnih časih: pred cepljenjem, na dan drugega cepljenja (21. dan) in 21 dni kasneje (na 42. dan).
The study showed that Pandemrix containing 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response that met these criteria.
Študija je pokazala, da zdravilo Pandemrix, vsebujoče 3, 75 mikrograma hemaglutinina in adjuvans, privede do protitelesnega odziva, ki zadovolji to merilo.
The most common side effects with Pandemrix (occurred with 1 in 10 doses or more of the vaccine) are headache, arthralgia (joint pain), myalgia (muscle pain), reactions at the site of the injection (hardening, swelling, pain and redness), fever and fatigue (tiredness).
Najpogostejši neželeni učinki zdravila Pandemrix (do katerih je prišlo pri 1 ali več odmerkih cepiva izmed 10) so glavobol, artralgija (bolečine v sklepih), mialgija (bolečine v mišicah), reakcije na mestu injiciranja (zatrdlina, oteklina, bolečina, rdečina), zvišana telesna temperatura ter utrujenost.
For the full list of all side effects reported with Pandemrix, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Pandemrix, glejte navodilo za uporabo.
Pandemrix should not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at trace (very low) levels in the vaccine, such as eggs, chicken protein, ovalbumin (a protein in egg white), formaldehyde, gentamicin sulphate (an antibiotic) and sodium deoxycholate.
Zdravilo Pandemrix se ne sme dajati osebam, ki so imele v preteklosti anafilaktično reakcijo (resno alergijsko reakcijo) na katero koli izmed sestavin cepiva ali na katero koli od snovi, ki se v sledeh nahajajo v cepivu, kot na primer na jajca, piščančje beljakovine, ovalbumin (beljakovino v beljaku), formaldehid, gentamicinijev sulfat (antibiotik) in natrijev deoksiholat.
The CHMP decided that Pandemrix’ s benefits are greater than its risks for the prophylaxis of influenza in an officially declared pandemic situation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Pandemrix pri preprečevanju gripe v uradno razglašenih pandemičnih razmerah večje od z njim povezanih tveganj.
The Committee recommended that Pandemrix be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Pandemrix odobri dovoljenje za promet.
Pandemrix has been authorised under ‘ Exceptional Circumstances’.
Zdravilo Pandemrix je bilo odobreno v „ izjemnih okoliščinah “.
What information is still awaited for Pandemrix?
Katere informacije o zdravilu Pandemrix še pričakujemo?
If a pandemic is declared, the company that makes Pandemrix will include the flu strain responsible in the vaccine.
V primeru razglasitve pandemije bo podjetje, ki izdeluje zdravilo Pandemrix, v cepivo vključilo pandemični sev virusa gripe.
It will then collect information on the safety and effectiveness of the final pandemic vaccine, and submit this to the CHMP for evaluation.
Tedaj bodo zbrali informacije o varnosti in učinkovitosti končnega pandemičnega cepiva in jih predložili v oceno CHMP.
Which measures are being taken to ensure the safe use of Pandemrix?
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Pandemrix?
If Pandemrix is used during a pandemic, the company that makes it will collect information on the safety of the vaccine while it is being used.
Če se bo zdravilo Pandemrix uporabljalo med pandemijo, bo podjetje, ki ga izdeluje, zbralo informacije o varnosti cepiva med njegovo uporabo.
Other information about Pandemrix:
Druge informacije o zdravilu Pandemrix:
The European Commission granted a marketing authorisation valid throughout the EU for Pandemrix to GlaxoSmithKline Biologicals s. a. on 20 May 2008.
Evropska komisija je dovoljenje za promet z zdravilom Pandemrix, veljavno po vsej Evropski uniji, odobrila družbi GlaxoSmithKline Biologicals s. a. dne 20. maja 2008.
The full EPAR for Pandemrix can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pandemrix je na voljo tukaj.
emulsion (adjuvant): vial (glass)
50 vial (suspenzija) 2 x 25 vial (emulzija)
Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Pandemrix suspenzija in emulzija za emulzijo za injiciranje cepivo proti pandemični gripi (H5N1) z delci virionov, inaktivirano (z adjuvansom)
Split influenza virus, inactivated, containing antigen* equivalent to:
Inaktivirane delce virusa gripe z vsebnostjo antigena *, ki ustreza:
Pandemic influenza vaccine should be used in accordance with official guidance (see sections 4.2 and 5.1).
Cepivo proti pandemični gripi je treba uporabljati v skladu z uradnimi smernicami (glejte poglavji 4. 2 in 5. 1).
Method of administration 2 Immunisation should be carried out by intramuscular injection.
Način uporabe 2 Cepivo je treba injicirati v mišico.
Pandemrix should not be given at the same time as other vaccines.
Cepiva Pandemrix se ne sme uporabljati sočasno z drugimi cepivi.
However, if co-administration with another vaccine is indicated, immunisation should be carried out on separate limbs.
Če je sočasno cepljenje indicirano, je treba drugo cepivo injicirati v drugo okončino.
No data have been generated in pregnant women with Pandemrix or with any other vaccine that contains the AS03 adjuvant
O uporabi cepiva Pandemrix ali kateregakoli drugega cepiva z adjuvansom AS03 pri nosečnicah ni podatkov.
Pandemrix may be used during lactation.
Cepivo Pandemrix se lahko uporablja med dojenjem.
3 4.7 Effects on ability to drive and use machines
3 4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Adverse reactions from clinical trials with the mock-up vaccine are listed here below (see section 5.1 for more information on mock-up vaccines).
V nadaljevanju so navedeni neželeni učinki modelnega (“ mock- up ”) cepiva iz kliničnih preskušanj (za več podatkov o modelnih cepivih glejte poglavje 5. 1).
General disorders and administration site conditions Very common: induration, swelling, pain and redness at the injection site, fever, fatigue Common: shivering, influenza like illness, injection site reactions (such as warmth, pruritus) Uncommon: malaise
Splošne težave in spremembe na mestu aplikacije Zelo pogosti: induracija, oteklina, bolečina in rdečina na mestu injiciranja, zvišana telesna temperatura, utrujenost Pogosti: drgetanje, gripi podobna bolezen, reakcije na mestu injiciranja (kot so občutek toplote, srbenje) Občasni: splošno slabo počutje
No post-marketing surveillance data are available following Pandemrix administration.
Podatki o spremljanju cepiva Pandemrix po pridobitvi dovoljenja za promet niso na voljo.
4 From Post-marketing surveillance with interpandemic trivalent vaccines, the following adverse reactions have been reported:
4 Med spremljanjem interpandemičnih trivalentnih cepiv po pridobitvi dovoljenja za promet so poročali o naslednjih neželenih učinkih:
This section describes the clinical experience with the mock-up vaccines following a two-dose administration.
V tem poglavju so navedene klinične izkušnje pri cepljenju z dvema odmerkoma modelnih (“ mock - up ”) cepiv.
Immune response against vaccine strain contained in Pandemrix (A/ Vietnam/ 1194/ 2004 (H5N1)):
Imunski odziv proti cepilnemu sevu, ki ga vsebuje cepivo Pandemrix (A/ Vietnam/ 1194/ 2004 (H5N1)):
In a consistency study, more than 900 subjects aged 18-60 years received Pandemrix following a 0, 21 days schedule.
V študiji konsistentnosti je cepivo Pandemrix po shemi 0. in 21. dan prejelo več kot 900 oseb, starih od 18 do 60 let.
Twenty-one days after the first and second dose of the vaccine, the seroprotection rates, seroconversion rates and seroconversion factors for anti-haemagglutinin (anti-HA) antibody were as follows:
Enaindvajset dni po cepljenju s prvim in drugim odmerkom cepiva so bili deleži serološke zaščite, deleži serokonverzije in faktorji serokonverzije za antihemaglutininska (anti- HA) protitelesa naslednji:
anti-HA antibody Seroprotection rate* † Seroconversion rate† Seroconversion factor† * anti-HA ≥ 1:40
anti- HA protitelesa Delež serološke zaščite * † Delež serokonverzije † Faktor serokonverzije † * anti- HA ≥ 1: 40
after 1st dose 44.5% 42.5% 4.1
21 dni po prvem odmerku 44, 5% 42, 5% 4, 1
after 2nd dose 94.3% 93.7% 39.8
21 dni po drugem odmerku 94, 3% 93, 7% 39, 8
† seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥ 1:40; seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥ 1:40, or who were seropositive at pre-vaccination and have a 4-
† Delež serološke zaščite: delež oseb s titrom inhibicije hemaglutinacije (IH) ≥ 1: 40; delež serokonverzije: delež oseb, ki so bile pred cepljenjem seronegativne in imajo po cepljenju zaščitni titer ≥ 1: 40, ali so bile pred cepljenjem seropozitivne in imajo 4- kraten porast titra; faktor serokonverzije: razmerje med geometrično sredino (GMS) titra po cepljenju in GMS titra pred cepljenjem.
Twenty-one days after administration of the second dose, 96.0% of subjects had a 4-fold increase in serum neutralising antibody titres.
5 Enaindvajset dni po cepljenju z drugim odmerkom je 96, 0% oseb imelo 4- krat večji titer nevtralizacijskih protiteles v serumu.
In a dose finding study in subjects aged 18-60 years, 50 subjects received a dose of 3.75 micrograms HA/ AS03 in a volume of 1 ml at 0 and 21 days.
V študiji za določitev odmerka je 50 oseb, starih od 18 do 60 let, prejelo odmerek 3, 75 mikrogramov HA/ AS03 v 1 ml, in sicer na 0. in 21. dan.
The seroprotection rates, seroconversion rates and seroconversion factors for anti-haemagglutinin (anti-HA) antibody at day 42 (post dose 2) and day 180 (persistence) were as follows:
Deleži serološke zaščite, deleži serokonverzije in faktorji serokonverzije za antihemaglutininska (anti- HA) protitelesa po 42 (po prejemu 2. odmerka) in 180 dneh (persistenca) so bili naslednji:
Seroprotection rate* † Seroconversion rate† Seroconversion factor† * anti-HA ≥ 1:40
Delež serološke zaščite * † Delež serokonverzije † Faktor serokonverzije † * anti- HA ≥ 1: 40
In the dose finding study the seroprotection rate, seroconversion rate and seroconversion factor against H5N1 drift variants 21 days after the second dose were as follows:
V študiji za določitev odmerka so bili 21 dni po cepljenju z drugim odmerkom delež serološke zaščite, delež serokonverzije in faktor serokonverzije proti zdrsnim variantam H5N1 naslednji: